Maximum quantity allowed is 999
请选择数量
CAS RN: 51781-21-6 | 產品號碼: C3015
Carteolol Hydrochloride
×
![]()
×
| 包裝 | 價格 | 同一天 | 2-3个工作日 |
|---|---|---|---|
| 50MG |
NT$4,920
|
10 | 30 |
| 250MG |
NT$17,840
|
9 | 25 |
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | C3015 |
| 純度/分析方法 | >98.0%(T)(HPLC) |
| 分子式 / 分子量 | C__1__6H__2__4N__2O__3·HCl = 328.84 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Room Temperature (Recommended in a cool and dark place, <15°C) |
| 包裝和容器 | 50MG-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 51781-21-6 |
| 相關CAS RN | 51781-06-7 |
| Reaxys-RN | 5784965 |
| PubChem Substance ID | 253662438 |
| Merck Index(14) | 1866 |
| MDL編號 | MFCD00941499 |
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
性質
| 熔點 | 278 °C |
| 水溶性 | Soluble |
| 溶解性（微溶於） | Methanol |
| 溶解性（不溶於） | Ethanol, Ether |
GHS
| 圖形表示 |
|
| 信號詞 | Warning |
| 危險性說明 | H302 : Harmful if swallowed. H361 : Suspected of damaging fertility or the unborn child. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
相關法規
| RTECS # | VC8282000 |
運輸資料
| HS編碼* | 2933.79-000 |
Application
Carteolol Hydrochloride: A Nonselective β-Adrenoceptor Antagonist (Blocker)
Carteolol hydrochloride (OPC-1085) is a nonselective β-adrenoceptor antagonist (blocker) with intrinsic sympathomimetic activity (ISA). Carteolol effectively reduces intraocular pressure (IOP), and is used for the treatment of glaucoma. Recently, some formulations for ocular controlled delivery of carteolol hydrochloride have been developed. (The product is for research purpose only.)
References
- Cardiovascular studies of 5-(3-tert-butylamino-2-hydroxy)propoxy-3,4-dihydrocarbostyril hydrochloride (OPC-1085), a new potent β-adrenergic blocking agent
- Cellular and molecular remodeling in a heart failure model treated with the β-blocker carteolol
- Metabolism of carteolol by cDNA-expressed human cytochrome P450
- Comparison of the analysis of β-blockers by different techniques
- Poly(ε-caprolactone) nanocapsules in carteolol ophthalmic delivery
- Designing dendrimers for ocular drug delivery
考研文獻
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。